Pharma & Biotech Global Week in Review 6 July 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Gemzar (Gemcitabine) – Brazil: Ruling gives security to production of generic Gemzar (IP tango)

Traditional knowledge and genetic resources – developing IPRs – 19 developing nations meet in Bali (IP Komodo Dragon)

Aricept (Donepezil) – US: Supreme Court vacates Federal Circuit opinion on declaratory judgment jurisdiction: Eisai v. Teva Pharms. USA (Orange Book Blog)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Traditional knowledge and genetic resources – developing IPRs – 19 developing nations meet in Bali (IP Komodo Dragon)

Twelve more nations, EU, sign Nagoya Protocol (IP Watch)

Australia: Update on Australian Senate gene patent inquiry (Patentology)

Canada: Amending Canada’s Access to Medicines Regime (CAMR): The new fate of Bill C-393 (IP Watch)

EU: Negative term SPC – A handy note on Case C-125/10 Merck (The SPC Blog) (EPLAW)

Italy: Milan Court revokes patent on second medical use of known drug: IBSA Institut Biochimique SA v. Pharmacia & Upjohn in liquidazione and Pfizer Italia s.r.l (Kluwer Patent Blog)

US: IPO releases list of top 300 patent holders for 2010 (Patent Docs)

US: Supreme Court to hear more patent cases in October 2011 term: Mayo v Prometheus; Kappos v Hyatt; Caraco v Novo Nordisk (Inventive Step)

US: In pleading inequitable conduct, inventor’s citation to withheld reference does not establish knowledge of reference sufficient to satisfy FRCP 9(b): Fred Hutchinson Cancer Research Center, et. al. v. Biopet Vet Lab, Inc., et. al. (Docket Report)

US moves closer to Australia on assignment of employee inventions: Bayh-Dole no saviour for government-funded research institutes: Board of Trustees for Leland Stanford Junior University v Roche Molecular Systems, Inc (IP Whiteboard)

US: Stem Cell Research Advancement Act of 2011, H.R. (Patent Baristas)

US: FDA’s Chief Counsel, Ralph Tyler, set to leave FDA (FDA Law Blog)

US: Docs at BIO: Steve Burrill’s state of the biotechnology industry report 2011 (Patent Docs)

US: Counterfeiting: White House IP Czar Victoria Espinel on working with corporations (BIOtechNOW)

US: Banning gene patents will promote innovation? (BIOtechNOW)

 

Products

2CM (Dicreatine malate) – US: CAFC: Email fails as evidence of conception: Creative Compounds v. Starmark (IPBiz)

Angiomax (Bivalirudin) – US: Lobbying for a patent term extension: Medicines Company v Kappos (Patently-O)

Aricept (Donepezil) – US: Supreme Court vacates Federal Circuit opinion on declaratory judgment jurisdiction: Eisai v. Teva Pharms. USA (Orange Book Blog)

Atorvastatin – Spain: Supreme Court sheds light on ‘implicit’ disclosure (Kluwer Patent Blog)

Diphoterine skin wash – US: FDA is sued over product designation determination; lawsuit seeks device declaration and to vacate FDA’s drug findings (FDA Law Blog)

Gemzar (Gemcitabine) – Brazil: Ruling gives security to production of generic Gemzar (IP tango)

Latanoprost – Italy: Pfizer: Abuse of dominant position? (2) (PatLit)

Lidoderm (Lidocaine) – US: Delaware District Court decision in Endo Pharmaceuticals patent case favors Watson (GenericsWeb)

Lidoderm (Lidocaine) – US: Endo files patent infringement suit against Watson in response to Para IV challenge (Patent Docs)

Lipitor (Atorvastatin) – UK: English Patent Court grants temporary restraining order against Teva on short notice – Pfizer threatens pharmacies with legal action over generic Atorvastatin supply (Kluwer Patent Blog) (GenericsWeb)

Lipitor (Atorvastatin) – US: Pfizer files patent infringement complaint against Aurobindo in response to Para IV certification (Patent Docs)

Lucentis (Ranibizumab) – UK: EWHC (Pat): Counsel for disputants most not teach experts to become partisan, warns judge: MedImmune v Novartis (PatLit) (IPKat)

Patanol (Olopatadine) – US: Wockhardt receives tentative US FDA approval for generic version (GenericsWeb)

Pramipexol – Spain: Court of Appeal of Barcelona lifts preliminary injunction ruling ‘omnibus’ claims granted under old Patent Act not enforceable (Kluwer Patent Blog)

Pulmicort Respules (Budesonide) – US: AstraZeneca files patent infringement complaint against Watson Laboratories in response to Para IV challenge (Patent Docs)

Silenor (Doxepin) – US: Somaxon Pharmaceuticals files patent infringement complaint against Mylan in response to ANDA filing (Patent Docs) (GenericsWeb)

Solaraze (Diclofenac) – US: Is information contained in a Paragraph IV certification notice letter accompanied by an offer of confidential access subject to public disclosure? One District Court has an answer: Nycomed v Tolmar (FDA Law Blog)

Trizivir (Abacavir) – US: ViiV Healthcare files patent infringement complaint against Lupin in response to Para IV certification filing (Patent Docs)

Welchol (Colesevelam) – US: Glenmarks settles litigation with Daiichi Sankyo, Genzyme (GenericsWeb)

Xeloda (Capecitabine) – US: Hoffman-La Roche files patent infringement suits against Accord Healthcare, Teva and Roxane following Para IV certification filing (Patent Docs)

Zyprexa (Olanzapine) – UK: Eli Lilly asks judge to reject generics firm’s UK Zyprexa case (GenericsWeb)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: